MRNA ▼ -4.2% - Moderna, Inc. $MRNA d/g Sell @ Citi Citi analyst Geoff Meacham downgraded Moderna to Sell from Neutral with a price target of $80, up from $60. The firm cites valuation for the downgrade with the shares up 222% since the results of the INTerpath-001 trial. Moderna now has a market cap similar to Regeneron despite "materially lower expected revenue and earnings," the analyst tells investors in a research note. 30-SEP-2026 05:27 AM ET